What happens when a highly interdisciplinary and integrated team of scientists, business leaders and students work together across fields of fundamental science, discovery, development, and finance? In the case of Monopar Therapeutics, a Chemistry of Life Processes Institute-affiliated spin-out, it leads to a record-breaking initial public offering.

Last month, Monopar (MNPR), a clinical stage biopharmaceutical company that develops proprietary therapeutics for cancer, experienced the “best first-day pop for an IPO since Baidu in 2005,” according to Nasdaq News. The company’s stock price rocketed 231 percent from its initial offering, reaching a market valuation of $289 million on its first day.

“It’s been a remarkable journey from the start,” says Chandler Robinson, MD, CEO of Monopar, and member of CLP’s Executive Advisory Board.

Read the rest of this article.

X